We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Nov 2023
  • Code : CMI5810
  • Pages :130
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

The global bacterial sialadenitis market size is projected to reach US$ 664.4 million by 2030, from US$ 467.8 million in 2023, growing at a CAGR of 5.1% during the forecast period.

Bacterial sialadenitis is an infection of the salivary glands, typically caused by bacterial pathogens. The salivary glands produce saliva, which is essential for lubricating the mouth, aiding in digestion, and preventing tooth decay. Bacterial sialadenitis most commonly affects the parotid glands, which are located on the sides of the face, just in front of and below the ears. The infection occurs when bacteria enter and multiply within the salivary ducts or the glandular tissue itself. This can lead to swelling, pain, and tenderness in the affected gland, as well as other symptoms such as fever, redness, and pus drainage if an abscess forms.

In addition, the increasing use of antibiotics is also contributing to the growth of the market. Antibiotics can kill beneficial bacteria in the mouth, which can make it easier for harmful bacteria to cause infection. 

The global bacterial sialadenitis market is segmented by type, type of bacteria, gland type, drug class, distribution channel, and region. By type, the market is segmented into acute and chronic. Acute sialadenitis is a sudden inflammation of the salivary glands, while chronic sialadenitis is a long-term inflammation of the salivary glands. Acute sialadenitis is the most common type of bacterial sialadenitis, accounting for a major share of the market.

Bacterial sialadenitis Market Regional Insights

  • The European market is expected to be the second-leading market during the forecast period. The rising geriatric population in the region is one of the major factor expected to drive the market growth as this age group is more prone of bacterial infections.
  • The Asia Pacific market is expected to be the fastest-growing market during the forecast period. The high growth of the market in the region is attributed to the increasing prevalence of bacterial sialadenitis in developing countries such as China, India, and in developed countries such as Japan.
  • The Middle East & Africa market is expected to be the least-growing market during the forecast period. The low growth of the market in the region is attributed to the low prevalence of bacterial sialadenitis in the region. Additionally, the limited availability of healthcare facilities in the region is expected to hamper the growth of the market.

Figure 1. Global Bacterial sialadenitis Market Share (%), by Region, 2023


To learn more about this report, request a free sample copy

Analyst Viewpoint:

Ongoing research is focused on gaining a deeper understanding of the mechanisms behind bacterial sialadenitis, developing more effective treatments, and exploring preventive measures. This includes investigating the role of antibiotics, salivary gland surgery, and advancements in imaging techniques. Individuals need to adopt prevention strategies such as promoting good oral hygiene, maintaining proper hydration, and managing underlying conditions that increase the risk of bacterial sialadenitis.

Bacterial sialadenitis Market Drivers

  • Bacterial sialadenitis is a condition characterized by inflammation of the salivary glands caused by bacterial infection. The market drivers for bacterial sialadenitis include several factors that contribute to its prevalence, diagnosis, and treatment. Here are some of the key drivers:
  • Increasing prevalence of bacterial infections: Bacterial infections, including those affecting the salivary glands, are a common health concern. The rise in bacterial infections due to factors such as poor oral hygiene, immunocompromised states, and the spread of antibiotic-resistant strains contributes to the increased incidence of bacterial sialadenitis.
  • Aging population: The elderly population is more susceptible to bacterial sialadenitis due to age-related changes in the salivary glands and immune system. As the global population continues to age, the prevalence of bacterial sialadenitis is likely to increase, driving the demand for diagnosis and treatment options.
  • Advances in diagnostic techniques: Improved diagnostic techniques, such as imaging modalities (ultrasound, CT scan, MRI) and microbiological testing, have enhanced the accuracy and early detection of bacterial sialadenitis. These advancements enable healthcare professionals to promptly identify and treat the condition, leading to an increased demand for diagnostic services.

Bacterial sialadenitis Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2022: US$ 467.8 Mn
Historical Data for: 2018 to 2022 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.1% 2030 Value Projection: US$ 664.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
  • By Type: Acute and Chronic
  • By Type of Bacteria: Staphylococcus aureus, Streptococcus viridans, Pseudomonas aeruginosa, Escherichia coli, and Others
  • By Gland Type: Parotid, Submandibular, and Sublingual
  • By Drug Class: Antibiotics and Analgesics
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Ecommerce
Companies covered:

Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Allergan plc

Growth Drivers:
  • Increasing prevalence of bacterial infections
  • Aging population
  • Advances in diagnostic techniques
Restraints & Challenges:
  • Misdiagnosis and under diagnosis
  • Lack of standardized treatment guidelines
  • Antibiotic resistance and limited treatment options
  • Side effects and adverse events

Bacterial sialadenitis Market Opportunities

  • Development of targeted therapies: As our understanding of the underlying mechanisms of bacterial sialadenitis improves, there is an opportunity to develop targeted therapies specifically designed to combat the causative bacteria. Targeted therapies can offer improved efficacy and reduced side effects compared to broad-spectrum antibiotics, leading to better treatment outcomes and patient satisfaction.
  • Expansion of diagnostic capabilities: There is an opportunity to develop and commercialize advanced diagnostic tools and technologies for bacterial sialadenitis. This includes point-of-care tests, molecular diagnostics, and rapid diagnostic assays that can quickly and accurately identify the causative bacteria and guide appropriate treatment decisions. Enhanced diagnostic capabilities can streamline patient care and improve disease management.
  • Collaboration between academia and industry: Collaboration between academic research institutions, pharmaceutical companies, and medical device manufacturers can accelerate the development of new therapies, diagnostic tools, and treatment approaches for bacterial sialadenitis. By leveraging the expertise and resources of different stakeholders, innovative solutions can be brought to the market more efficiently, benefiting both patients and healthcare providers.

Bacterial sialadenitis Market Trends

  • Increasing incidence of antibiotic-resistant bacteria: Antibiotic resistance has become a global concern, including in the context of bacterial sialadenitis. There is a growing trend of antibiotic-resistant bacterial strains causing salivary gland infections, which can complicate treatment and increase the risk of treatment failure. This trend highlights the need for alternative treatment approaches, such as targeted therapies and combination therapies, to effectively manage bacterial sialadenitis.
  • Growing focus on personalized medicine: Personalized medicine, which tailors treatment to individual patients based on their unique characteristics, is gaining traction in various fields of medicine, including infectious diseases. In the context of bacterial sialadenitis, there is an increasing emphasis on identifying the specific causative bacteria and their antibiotic susceptibility patterns to guide personalized treatment decisions. This trend aims to optimize treatment outcomes and reduce the unnecessary use of broad-spectrum antibiotics.
  • Emphasis on oral hygiene and preventive measures: Good oral hygiene practices and preventive measures play a crucial role in reducing the risk of salivary gland infections, including bacterial sialadenitis. There is a growing trend of oral health education, awareness campaigns, and preventive interventions aimed at promoting proper oral hygiene and regular dental care. This trend recognizes the importance of preventive strategies in reducing the incidence and severity of bacterial sialadenitis.

Bacterial sialadenitis Market Restraints

  • Misdiagnosis and under diagnosis: Bacterial sialadenitis can often be misdiagnosed or underdiagnosed, as its symptoms may overlap with other conditions such as viral infections or salivary stones. The lack of specific symptoms and limited awareness among healthcare professionals can lead to delayed or incorrect diagnosis, resulting in suboptimal management of the condition.
  • Lack of standardized treatment guidelines: There is a lack of universally accepted and standardized treatment guidelines for bacterial sialadenitis. Treatment approaches may vary among healthcare providers, leading to inconsistency in patient care. The absence of clear guidelines can hinder effective treatment decision-making and contribute to variations in treatment outcomes.
  • Antibiotic resistance and limited treatment options: The emergence of antibiotic-resistant bacterial strains poses a significant challenge in the treatment of bacterial sialadenitis. The increasing prevalence of multidrug-resistant bacteria limits the effectiveness of conventional antibiotic therapies. This necessitates the development of alternative treatment strategies and targeted therapies to overcome resistance and improve treatment outcomes.
  • Side effects and adverse events: Antibiotic therapies used to treat bacterial sialadenitis can be associated with side effects and adverse events, such as gastrointestinal disturbances, allergic reactions, and antibiotic-associated diarrhea. The occurrence of these adverse events can impact patient adherence to treatment regimens and overall treatment satisfaction.

Figure 2. Global Bacterial sialadenitis Market Share (%), by Type of Bacteria, 2023


To learn more about this report, request a free sample copy

Top Companies in Bacterial sialadenitis Market

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Sanofi S.A.
  • Johnson & Johnson
  • Abbott Laboratories
  • Eli Lilly and Company
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Allergan plc

*Definition: Bacterial sialadenitis is an infection of the salivary glands, typically caused by bacterial pathogens. Treatment for bacterial sialadenitis typically involves antibiotics to target the underlying bacterial infection. In some cases, drainage of any abscess may be necessary. Maintaining good oral hygiene, staying well-hydrated, and addressing any underlying risk factors can help prevent bacterial sialadenitis from recurring.

Frequently Asked Questions

Misdiagnosis and under diagnosis, lack of standardized treatment guidelines, antibiotic resistance and limited treatment options, and side effects and adverse events of antibiotics, are some of the factors hampering the market development.

Increasing prevalence of bacterial infections, aging population, and advances in diagnostic techniques are some of the major factors driving the market development.

The leading drug class segment in the market is antibiotics. Antibiotics are commonly prescribed to treat bacterial sialadenitis and are a key component of the standard treatment regimen. They help to eliminate the bacterial infection and reduce inflammation in the salivary glands.

Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Allergan plc

The North America region is anticipated to have the highest share of the market over the projected period, attributing to factors such as developed healthcare infrastructure, access to medical services, and population demographics.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo